Evaluation of neopterin levels and kynurenine pathway in patients with acute coronary syndrome.
ST elevation myocardial infarction
acute coronary syndrome
indoleamine 2,3-dioxygenase
kynurenine
neopterin
troponin
tryptophan
Journal
Acute and critical care
ISSN: 2586-6060
Titre abrégé: Acute Crit Care
Pays: Korea (South)
ID NLM: 101726905
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
09
01
2023
accepted:
30
06
2023
medline:
1
9
2023
pubmed:
1
9
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
Coronary atherosclerosis is the leading cause of coronary artery disease. Several investigations have indicated that tear-sensitive plaques contain macrophages and T cells. Neopterin is an essential cellular immune response biomarker. The main goal of this study was to see if there were any changes in biomarkers like unconjugated pteridines, neopterin, and biopterin, as well as kynurenine pathway enzymes like indoleamine 2,3-dioxygenase (IDO), which catalyzes the rate-limiting step in tryptophan degradation, in patients with the acute coronary syndrome (ACS) caused by angiographic atherosclerosis. High-performance liquid chromatography was used to determine the amounts of neopterin, biopterin, and creatinine in urine samples, as well as tryptophan and kynurenine in serum samples. The enzyme-linked immunosorbent assay was used to assess the amounts of neopterin in serum samples. The measured parameters were evaluated between ACS patients and controls. The measured levels of neopterin, biopterin and the kynurenine to tryptophan ratio reflecting IDO activity, and the specifically known biomarkers such as cardiac troponin, creatine kinase, myoglobin, and natriuretic peptides are statistically higher in ACS patients compared to control subjects. On the other hand, the measured parameters are inadequate to classify the conventional kinds of ACS, ST-elevation- and non-ST-elevation- myocardial infarction. The study found that determining and using neopterin and IDO parameters as biomarkers in individuals with the ACS can support traditional biomarkers. However, it can be concluded that evaluating pteridine biomarkers solely have no privilege to clinical findings in ACS diagnosis and classification.
Sections du résumé
BACKGROUND
BACKGROUND
Coronary atherosclerosis is the leading cause of coronary artery disease. Several investigations have indicated that tear-sensitive plaques contain macrophages and T cells. Neopterin is an essential cellular immune response biomarker. The main goal of this study was to see if there were any changes in biomarkers like unconjugated pteridines, neopterin, and biopterin, as well as kynurenine pathway enzymes like indoleamine 2,3-dioxygenase (IDO), which catalyzes the rate-limiting step in tryptophan degradation, in patients with the acute coronary syndrome (ACS) caused by angiographic atherosclerosis.
METHODS
METHODS
High-performance liquid chromatography was used to determine the amounts of neopterin, biopterin, and creatinine in urine samples, as well as tryptophan and kynurenine in serum samples. The enzyme-linked immunosorbent assay was used to assess the amounts of neopterin in serum samples. The measured parameters were evaluated between ACS patients and controls.
RESULTS
RESULTS
The measured levels of neopterin, biopterin and the kynurenine to tryptophan ratio reflecting IDO activity, and the specifically known biomarkers such as cardiac troponin, creatine kinase, myoglobin, and natriuretic peptides are statistically higher in ACS patients compared to control subjects. On the other hand, the measured parameters are inadequate to classify the conventional kinds of ACS, ST-elevation- and non-ST-elevation- myocardial infarction.
CONCLUSIONS
CONCLUSIONS
The study found that determining and using neopterin and IDO parameters as biomarkers in individuals with the ACS can support traditional biomarkers. However, it can be concluded that evaluating pteridine biomarkers solely have no privilege to clinical findings in ACS diagnosis and classification.
Identifiants
pubmed: 37652862
pii: acc.2023.00024
doi: 10.4266/acc.2023.00024
pmc: PMC10497888
doi:
Types de publication
Journal Article
Langues
eng
Pagination
325-332Subventions
Organisme : Hacettepe University
ID : TDK -2019-17670
Références
Prog Neuropsychopharmacol Biol Psychiatry. 2023 Jan 10;120:110633
pubmed: 36089162
Clin Chem. 1997 Dec;43(12):2424-6
pubmed: 9439467
Eur Heart J. 2013 Sep;34(34):2689-96
pubmed: 23886918
Monaldi Arch Chest Dis. 2007 Jun;68(2):68-73
pubmed: 17886766
Circ J. 2004 Feb;68(2):114-20
pubmed: 14745144
Nihon Rinsho. 2006 Apr;64(4):625-32
pubmed: 16613178
Toxicol Mech Methods. 2011 Mar;21(3):231-5
pubmed: 21247367
Circulation. 2004 Sep 28;110(13):1747-53
pubmed: 15381646
Emerg Med Clin North Am. 2022 Nov;40(4):629-636
pubmed: 36396211
Atherosclerosis. 2008 Nov;201(1):176-83
pubmed: 18336825
Emerg Med Clin North Am. 2022 Nov;40(4):693-706
pubmed: 36396216
Am J Cardiol. 2004 Mar 1;93(5):627-9
pubmed: 14996595
Clin Lab. 2014;60(3):391-6
pubmed: 24697114
Int J Cardiol. 2006 Aug 10;111(2):318-20
pubmed: 16352358
Circulation. 2007 Jun 19;115(24):3071-8
pubmed: 17548728
Eur J Clin Invest. 2003 Jul;33(7):550-4
pubmed: 12814390
J Am Coll Cardiol. 1997 Sep;30(3):703-7
pubmed: 9283529
J Am Coll Cardiol. 2000 Mar 15;35(4):956-62
pubmed: 10732894
Sci Rep. 2020 Oct 12;10(1):17025
pubmed: 33046801
Eur Heart J. 2005 Mar;26(5):457-63
pubmed: 15684278
Ann Lab Med. 2019 May;39(3):284-290
pubmed: 30623620
Psychiatry Res. 2001 Sep 20;103(2-3):115-23
pubmed: 11549400
Am J Cardiol. 2003 Nov 15;92(10):1201-3
pubmed: 14609597
Ann Hematol. 2020 Jan;99(1):41-47
pubmed: 31760485
Psychoneuroendocrinology. 2009 Nov;34(10):1560-6
pubmed: 19540675
Eur J Clin Invest. 2015 Mar;45(3):247-54
pubmed: 25586781
Eur Heart J. 2011 Jun;32(11):1390-7
pubmed: 21345849
Asian Cardiovasc Thorac Ann. 2013 Aug;21(4):426-31
pubmed: 24570524
Ann Acad Med Singap. 2010 Mar;39(3):210-5
pubmed: 20372757